Synlait's back
OPINION: After years of financial turmoil, Canterbury milk processor Synlait is now back in business.
SYNLAIT MILK expects strong global demand for its lactoferrin to continue since it began commercially producing and selling the milk protein earlier this year.
Managing director John Penno says the response from customers about the performance of Synlait's lactoferrin in their product applications has been very positive.
"Our initial focus on its application in infant formula and over the counter nutraceutical products such as health tablets is paying off," he says.
"Globally, consumers are increasingly looking for nutritious and safe food that contributes to the long-term health and well-being of their families. Lactoferrin can help meet these needs."
Used in the manufacture of infant formula, health food and pharmaceutical products, the bioactive protein provides significant anti-inflammatory protection and other health benefits.
"It is an important step forward for the business. We have had interest for some time from customers looking to enhance the performance of lactoferrin as an ingredient in their infant formula products.
"By producing spray-dried lactoferrin, through a process which has been designed to protect its bio-activity and increase solubility, we are able to meet their needs," Penno says.
Following the upgrade of its Specialty Milks Dryer earlier this year, Synlait Milk became one of only two manufacturers world-wide with the capability to produce lactoferrin as a spray-dried powder.
Penno added that Synlait Milk is targeting 15 metric tonnes of spray dried lactoferrin sales in the current financial year.
The market for lactoferrin has grown from 45,000 kg's in 2001 to 185,000 kg's in 2012 and is projected to grow to 262,000 kg's in 2017.
A brilliant result and great news for growers and regional economies. That's how horticulture sector leaders are describing the news that sector exports for the year ended June 30 will reach $8.4 billion - an increase of 19% on last year and is forecast to hit close to $10 billion in 2029.
Funding is proving crucial for predator control despite a broken model reliant on the goodwill of volunteers.
A major milestone on New Zealand's unique journey to eradicate Mycoplasma bovis could come before the end of this year.
We're working through it, and we'll get to it.
The debate around New Zealand's future in the Paris Agreement is heating up.
A technical lab manager for Apata, Phoebe Scherer, has won the Bay of Plenty 2025 Young Grower regional title.